1887

Journal of Medical Microbiology logo

Volume 71, Issue 7

Introducing biomarkers for invasive fungal disease in haemato-oncology patients: a single-centre experience No Access

Abstract

The impacts of increased biomarker testing on antifungal prescribing have not yet been fully examined in a real-life setting.

Biomarkers for invasive fungal disease (IFD) have been shown to reduce antifungal prescriptions in neutropaenic haemato-oncology patients. Our study aimed to assess the real-life impacts of introducing a novel biomarker-based pathway, incorporating serum galactomannan and PCR, for pyrexial haemato-oncology admissions.

Patients with neutropaenic fever were identified prospectively after introduction of the new pathway from 2013–2015. A historical group of neutropaenic patients who had blood cultures taken from 2009–2012 was generated for comparison. Clinical details, including demographics, underlying diagnosis, investigations, radiology and antimicrobial treatment were obtained.

Prospective data from 308 patients were compared to retrospective data from 302 patients. The proportion of patients prescribed an antifungal medication was unchanged by the pathway (=0.79), but the pattern was different, with more patients receiving targeted antifungals (=0.04). A negative serum galactomannan test was not sufficient evidence to withhold therapy, with 17.2% of these episodes felt to have possible or probable IFD using the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) criteria. There was no difference in 30-day mortality (=0.21) or 1-year mortality (=0.57) following introduction of the pathway.

Biomarkers can be used safely as part of a multidisciplinary approach to the diagnosis of IFD in neutropaenic haemato-oncology patients. Whilst they do not necessarily result in antifungal therapy being withheld, they can allow more confident diagnosis of IFD and more specific antifungal therapy in selected cases.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): antifungal agents , aspergillosis , biomarkers , fungal infection and galactomannan
© 2022 The Authors
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001564
2022-07-12
2024-05-19
Loading full text...

Full text loading...

References

  1. Enoch DA, Yang H, Aliyu SH, Micallef C. The changing epidemiology of invasive fungal infections. Methods Mol Biol 2017; 1508:17–65 [View Article] [PubMed]
     [Google Scholar]
  2. Corzo-León DE, Satlin MJ, Soave R, Shore TB, Schuetz AN et al. Epidemiology and outcomes of invasive fungal infections in allogeneic haematopoietic stem cell transplant recipients in the era of antifungal prophylaxis: a single-centre study with focus on emerging pathogens. Mycoses 2015; 58:325–336 [View Article] [PubMed]
     [Google Scholar]
  3. Herbrecht R, Caillot D, Cordonnier C, Auvrignon A, Thiébaut A et al. Indications and outcomes of antifungal therapy in French patients with haematological conditions or recipients of haematopoietic stem cell transplantation. J Antimicrob Chemother 2012; 67:2731–2738 [View Article] [PubMed]
     [Google Scholar]
  4. Denning DW. Early diagnosis of invasive aspergillosis. Lancet 2000; 355:423–424 [View Article] [PubMed]
     [Google Scholar]
  5. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46:1813–1821 [View Article]
     [Google Scholar]
  6. Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis 2020; 71:1367–1376 [View Article] [PubMed]
     [Google Scholar]
  7. Micallef C, Aliyu SH, Santos R, Brown NM, Rosembert D et al. Introduction of an antifungal stewardship programme targeting high-cost antifungals at a tertiary hospital in Cambridge, England. J Antimicrob Chemother 2015; 70:1908–1911 [View Article] [PubMed]
     [Google Scholar]
  8. White PL, Linton CJ, Perry MD, Johnson EM, Barnes RA. The evolution and evaluation of a whole blood polymerase chain reaction assay for the detection of invasive aspergillosis in hematology patients in a routine clinical setting. Clin Infect Dis 2006; 42:479–486 [View Article] [PubMed]
     [Google Scholar]
  9. Barnes RA, White PL, Bygrave C, Evans N, Healy B et al. Clinical impact of enhanced diagnosis of invasive fungal disease in high-risk haematology and stem cell transplant patients. J Clin Pathol 2009; 62:64–69 [View Article] [PubMed]
     [Google Scholar]
  10. Barnes R, Earnshaw S, Herbrecht R, Morrissey O, Slavin M et al. Economic comparison of an empirical versus diagnostic-driven strategy for treating invasive fungal disease in immunocompromised patients. Clin Ther 2015; 37:1317–1328 [View Article] [PubMed]
     [Google Scholar]
  11. Morrissey CO, Chen SC-A, Sorrell TC, Milliken S, Bardy PG et al. Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial. Lancet Infect Dis 2013; 13:519–528 [View Article] [PubMed]
     [Google Scholar]
  12. Martinelli AW, Patil P, Wong VK, Enoch DA, Sander CR. A positive BAL galactomannan in non-haemato-oncology patients risks harmful overtreatment. J Med Microbiol 2019; 68:1766–1770 [View Article] [PubMed]
     [Google Scholar]
  13. Matthey F, Parker A, Rule SAJ, Wimperis JZ, Ardeshna KM et al. Facilities for the treatment of adults with haematological malignancies--’Levels of Care’: BCSH Haemato-Oncology Task Force 2009. Hematology 2010; 15:63–69 [View Article] [PubMed]
     [Google Scholar]
  14. Leeflang MMG, Debets-Ossenkopp YJ, Wang J, Visser CE, Scholten RJPM et al. Galactomannan detection for invasive aspergillosis in immunocompromised patients. Cochrane Database Syst Rev 2015CD007394 [View Article] [PubMed]
     [Google Scholar]
  15. Ansorg R, van den Boom R, Rath PM. Detection of Aspergillus galactomannan antigen in foods and antibiotics. Mycoses 1997; 40:353–357 [View Article] [PubMed]
     [Google Scholar]
  16. Martín-Rabadán P, Gijón P, Alonso Fernández R, Ballesteros M, Anguita J et al. False-positive Aspergillus antigenemia due to blood product conditioning fluids. Clin Infect Dis 2012; 55:e22–7 [View Article] [PubMed]
     [Google Scholar]
  17. Mori Y, Nagasaki Y, Kamezaki K, Takenaka K, Iwasaki H et al. High incidence of false-positive Aspergillus galactomannan test in multiple myeloma. Am J Hematol 2010; 85:449–451 [View Article] [PubMed]
     [Google Scholar]
  18. Marr KA, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 2005; 40:1762–1769 [View Article] [PubMed]
     [Google Scholar]
  19. Cornely OA. Galactomannan testing during mold-active prophylaxis. Clin Infect Dis 2014; 59:1703–1704 [View Article] [PubMed]
     [Google Scholar]
  20. Heafield S, Qualie M. PSS1 Medicines Optimisation and Stewardship PSS CQUIN Indicator [Internet]. 07/02/2020. [cited 2022 May 12]; 2020 https://www.england.nhs.uk/publication/pss1-meds-optimisation-pss-cquin-indicator/
  21. Agrawal S, Barnes R, Brüggemann RJ, Rautemaa-Richardson R, Warris A. The role of the multidisciplinary team in antifungal stewardship. J Antimicrob Chemother 2016; 71:ii37–ii42 [View Article] [PubMed]
     [Google Scholar]
  22. Barlow G, Allsup D, Sheard L, Hilton A, Lillie P et al. Biomarker Driven Antifungal Stewardship (BioDriveAFS) in Acute Leukaemia a Multi-Centre Randomised Controlled Trial to Assess Clinical and Cost Effectiveness [Internet]. NIHR Funding and Awards. 2021 [cited 2022 Apr 25]; 2021 https://fundingawards.nihr.ac.uk/award/NIHR132674
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.001564
Loading
Introducing biomarkers for invasive fungal disease in haemato-oncology patients: a single-centre experience
J. Med. Microbiol. 71, 001564 (2022); https://doi.org/10.1099/jmm.0.001564
/content/journal/jmm/10.1099/jmm.0.001564
/content/journal/jmm/10.1099/jmm.0.001564
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error